Clinical TrialID 3768

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616

Amyotrophic Lateral Sclerosis (ALS)

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
3768
Evidence Id
3768
Core Evidence Id
3768
Source Clinical Trial Id
3742
Herb2 Clinical Trial Id
HBCT003742
Nct Id
NCT03580616
Title
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status
Terminated
Phase
Phase 2
Study Result
No
Study Condition
Amyotrophic Lateral Sclerosis (ALS)
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: L-Serine
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
43
Outcome Measure
Dose tolerability based on subject reporting, Dose tolerability is based on subject interviews and diary assessment evaluating the presence or absence of adverse events, 6 months
Sponsor Collaborator
Elijah W. Stommel|Brain Chemistry Labs, Institute for Ethnomedicine
Funded By
OTHER
Location
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States
Other Id
D18095
Start Date
2018-10-24
Primary Completion Date
2022-08-03
Completion Date
2022-12-20
First Posted
2018-07-09
Results First Posted
Last Update Posted
2023-09-07
Study Document
Study Url
https://clinicaltrials.gov/study/NCT03580616
Title Cn
Title En
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
Bilingual Status
semi_complete